NHS rolls out ‘Biological Missile’ drug for resistant ovarian cancer. The first new targeted treatment in over 20 years
National Institute for Health and Care (NICE) has recommended mirvetuximab soravtansine (Elahere; AbbVie) for NHS use, marking the first new targeted therapy for platinum-resistant ovarian cancer in over two decades.
Hundreds of women with advanced ovarian cancer may benefit from a new, life-extending treatment on the NHS from this week, following a recommendation by NICE. Mirvetuximab soravtansine, marketed as Elahere and developed by AbbVie, is the first new targeted therapy for platinum-resistant ovarian cancer to be approved for NHS use in over 20 years. Offering renewed hope at a stage of disease where effective options have historically been limited.
Clinical Evidence and Eligibility
The NICE recommendation covers adult patients with folate receptor-alpha-positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of systemic treatment – patients whose disease has progressed within six months of platinum-based chemotherapy.
In a major global clinical trial involving eight NHS hospitals, mirvetuximab soravtansine delayed disease progression and prolonged survival. Patients receiving the drug lived an average of 16.5 months longer, compared with 12.8 months for those receiving chemotherapy. The treatment is administered as an intravenous infusion over two to four hours, once every three weeks.
The NHS estimates that up to 400 patients in England each year could benefit, with approximately 270 eligible in the first year, rising to around 420 by year three as access to the diagnostic biomarker test becomes more widely available across NHS trusts.
Tolerability and NHS Access
Because mirvetuximab soravtansine targets cancer cells more precisely than conventional chemotherapy, clinicians anticipate a more favourable side-effect profile for many patients. The treatment does carry adverse effects including vision impairment, fatigue, nausea, peripheral neuropathy, and dry eye, though these were generally considered manageable in trial data.
The drug will be available immediately through NHS England’s Cancer Drugs Fund, which has provided early access to innovative cancer treatments for more than 100,000 patients over the past decade. It will transition to routine NHS commissioning 90 days after NICE publishes final guidance.
Significance of the Approval
Ovarian cancer is frequently diagnosed at an advanced stage, and platinum-resistant disease, where tumours no longer respond to standard first-line chemotherapy, which represents one of the most challenging scenarios in gynaecological oncology. The absence of new approved targeted options for this population over the past two decades has made the NICE recommendation a landmark moment for oncologists and patient groups alike.
For eligible women, mirvetuximab soravtansine offers a clinically meaningful extension of survival alongside the prospect of a less debilitating treatment experience – a combination that has historically been difficult to achieve in this setting.
